DOCSLIB.ORG

Identification of Genes Involved in Hematopoietic Stem Cell Differentiation and Leukemia Differentiation and Leukemia Jasjeet Bhullar [email protected]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Genes Involved in Hematopoietic Stem Cell Differentiation and Leukemia Differentiation and Leukemia Jasjeet Bhullar Bhullar@Marshall.Edu Marshall University Marshall Digital Scholar Theses, Dissertations and Capstones 1-1-2011 Identification of Genes Involved in Hematopoietic Stem Cell Differentiation and Leukemia Differentiation and Leukemia Jasjeet Bhullar [email protected] Follow this and additional works at: http://mds.marshall.edu/etd Part of the Hematology Commons, and the Medical Cell Biology Commons Recommended Citation Bhullar, Jasjeet, "Identification of Genes Involved in Hematopoietic Stem Cell Differentiation and Leukemia Differentiation and Leukemia" (2011). Theses, Dissertations and Capstones. Paper 23. This Dissertation is brought to you for free and open access by Marshall Digital Scholar. It has been accepted for inclusion in Theses, Dissertations and Capstones by an authorized administrator of Marshall Digital Scholar. For more information, please contact [email protected]. Identification of genes involved in hematopoietic stem cell differentiation and leukemia Dissertation submitted to the Graduate College of Marshall University in partial fulfillment of the requirement for the degree of Doctor of Philosophy by Jasjeet Bhullar Approved by: Dr. Vincent E Sollars, Ph.D., Committee Chairperson Dr. Richard Niles, Ph.D. Dr. Todd Green, Ph.D. Dr. Beverly Delidow, Ph.D. Dr. Susan Jackman, Ph.D. Department of Biochemistry and Microbiology, Marshall University Joan C. Edwards School of Medicine Huntington, West Virginia April 2011 ABSTRACT Hematopoiesis is maintained by a proper balance between self renewal and multipotent differentiation of the hematopoietic stem cells (HSC). Acute myelogenous leukemia (AML) is characterized by the blockage in the differentiation of HSC, while self renewal and proliferation is preserved. It is important to understand the mechanisms involved in the inhibition of hematopoietic differentiation and maintenance of the HSC state in order to develop better therapies for AML. In these studies I have explored the role of Hsp90, omega-3 fatty acids and YB-1 in hematopoietic differentiation. EML, a hematopoietic precursor cell line, was used as a model for the hematopoietic system in these studies. My preliminary data showed the activation of Wnt signaling upon inhibition of Hsp90 in EML cells. This data suggested the involvement of Hsp90 in the regulation of Wnt signaling in EML cells. Moreover, my initial data with fatty acid studies indicated that omega-3 fatty acids could affect Wnt signaling in EML cells. Unfortunately, further progression of both these studies was marred by variability in my data. In my latest study, I have identified YB-1 as a marker involved in the maintenance of the hematopoietic stem cell state. YB-1 was found to be highly expressed in the EML cell line and in the mouse bone marrow-derived HSC and myeloid progenitor cells. In addition, YB-1 expression was downregulated during myeloid differentiation in retinoic acid (RA) and granulocyte macrophage colony stimulating factor (GM-CSF) treated EML cells, as well as in the granulocytes derived from mouse bone marrow. Further, abnormal YB-1 expression was observed in myeloid leukemic cell lines. Knockdown of YB-1 expression and arsenic trioxide treatment (As 2O3) in erythroleukemic, K562 cell line resulted in apoptosis and inhibition of cell proliferation. Most importantly, these treatments led to the induction of megakaryocytic differentiation in these cells. Overall my data suggests that increased expression of YB-1 in the leukemic cells contributes to the leukemic cell properties by promoting cell proliferation, cell survival and blocking cell differentiation. Thus, YB-1 could be a potential target for therapy in myeloid leukemia. ii DEDICATION I would like to dedicate this work to my parents, Satpal and Jasmeet Bhullar. Without their knowledge, wisdom, and guidance, I would not have the goals I have; to strive and be the best to reach my dreams. iii ACKNOWLEDGEMENTS I would like to thank my family for being there for me when I needed them the most. It is due to their encouragement, support and love I was able to come so far to pursue my dream. I would like to sincerely thank my brother, Simarjeet Bhullar who was responsible for giving a direction to my life. I have always admired his courage and determination and followed in his footsteps. I love my parents and I sincerely appreciate their patience and support. I can not thank enough my husband, Dr. Sandeep Joshi, with whose support I was able to achieve my goal of graduate education. He motivated, encouraged and guided me through this. He took care of our son while I was working on my dissertation. I would like to thank almighty god for giving me his blessings and a wonderful son Prateik. I would also like to thank my mother- and father-in-law who took care of things at home while I was writing. I would like to thank all my labmates for some of the quality time we spent during the course of this journey particularly Dr. Jennifer Napper, Dr. Mindy Varney, Harsh Pratap, Ayah Arafa, James Buchanan and Jonathan Lewis. I would thank the BMS program for giving me this opportunity to fulfill my goal of graduate education. Also, I’d like to thank all my BMS friends who made me cherish my graduate school experience. I am going to miss all of you. I would like to thank my advisor, Dr. Sollars for guiding me through this work. His patience and support is appreciated. I would thank my committee: Dr. Susan Jackman, Dr. Beverely Delidow, Dr. Richard Niles and Dr. Green who helped me become a better scientist. It’s through their guidance I strived hard to learn more. iv TABLE OF CONTENTS TITLE PAGE ................................................................................................................................. i ABSTRACT ................................................................................................................................... ii DEDICATION PAGE ................................................................................................................. iii ACKNOWLEDGEMENTS ........................................................................................................ iv TABLE OF CONTENTS ..............................................................................................................v LIST OF FIGURES .................................................................................................................... vii LIST OF ABBREVIATIONS .......................................................................................................x CHAPTER ONE: INTRODUCTION ..........................................................................................1 Hematopoiesis ...........................................................................................................................1 Acute Myelogenous Leukemia ................................................................................................4 Stress response .........................................................................................................................6 Hsp90 isoforms and structure .................................................................................................8 Role of Hsp90 in cancer .........................................................................................................12 Hsp90 inhibitors ....................................................................................................................13 Y Box Protein (YB-1) .............................................................................................................15 YB-1 expression, structure and function .............................................................................16 Biological role of YB-1 ...........................................................................................................19 Role of YB-1 in cancer ...........................................................................................................20 Role of YB-1 in hematological malignancies .......................................................................22 Wnt signalling ........................................................................................................................24 Wnt signalling and hematopoietic stem cells .......................................................................26 Omega fatty acids and cancer ...............................................................................................28 CHAPTER TWO: YB-1 expression and function in early hematopoiesis and leukemia ....32 ABSTRACT ............................................................................................................................33 INTRODUCTION..................................................................................................................34 MATERIALS AND METHODS ..........................................................................................36 RESULTS ...............................................................................................................................42 v DISCUSSION .........................................................................................................................54 CHAPTER THREE: Activation of the canonical Wnt signaling in hematopoietic precursor, EML cell line upon Hsp90 inhibition ......................................................................60 ABSTRACT ............................................................................................................................60 INTRODUCTION..................................................................................................................61
Load more

Recommended publications
  • 1. Introduction and Literature Review
    1. Introduction and literature review 1.1 Introduction 1.1.1 Defintion of blood Blood is described as a specialized connective tissue,which circulates in a closed system of blood vessels. (Monica.C, 2009) 1.1.2 Blood components Plasma is 55% of the total blood ,plasma cosist of albumin,globulin,water,electrolyte and many other organic and inorganic substances. (Monica.C, 2009) Blood cells is 45% of total blood and encompass;White blood cells(WBCs),Red blood cells(RBCs),and Platelets(Plts). (Monica.C, 2009) 1.1.3 Function of blood -Respiration: transport of oxygen from the lung to tissues and carbon dioxide from tissues to the lungs. -Excreation:transport of metabolic waste to the lungs,kidneys,skin and intestine for removal. - Maintain of normal acid –base balance. -Nutrition of body . -Part of immune system. (Monica.C, 2009) 1 1.1.4 Haemopoiesis Is the general aspect of blood cells formation. (Monica.C, 2009) Haemopoiesis occurs at different anatomical sites the course of development from embryonic life to adult life this site is, up to 2 month of gestation.The haemopoiesis occurs in yolk sac of the embryo.This period called (Myeloblastic period). (Monica.C, 2009) 2-7 month of gestation, this period called (Haepatic period). (Monica.C, 2009) Only important site of all hemopoiesis site after birth,an exception is lymphocyte production which occur in other organ in addition to the bone marrow.This period called(Myeloid period). (Monica.C, 2009) 1.1.5 Development of haemopoiesis The general most commonly accepted view is that blood cells development from small population of stem cells.
    [Show full text]
  • Differentiation of Pluripotent Cells Differenzierung Pluripotenter Zellen Différenciation De Cellules Pluripotentes
    (19) TZZ Z_¥_T (11) EP 2 401 364 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 5/0781 (2010.01) C12N 5/071 (2010.01) 22.04.2015 Bulletin 2015/17 (86) International application number: (21) Application number: 10707179.7 PCT/US2010/025776 (22) Date of filing: 01.03.2010 (87) International publication number: WO 2010/099539 (02.09.2010 Gazette 2010/35) (54) DIFFERENTIATION OF PLURIPOTENT CELLS DIFFERENZIERUNG PLURIPOTENTER ZELLEN DIFFÉRENCIATION DE CELLULES PLURIPOTENTES (84) Designated Contracting States: • WANG LISHENG ET AL: "Endothelial and AT BE BG CH CY CZ DE DK EE ES FI FR GB GR hematopoietic cell fate of human embryonic stem HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL cells originates from primitive endothelium with PT RO SE SI SK SM TR hemangioblastic properties" IMMUNITY, CELL PRESS, US LNKD- DOI:10.1016/J.IMMUNI. (30) Priority: 27.02.2009 US 156304 P 2004.06.006, vol. 21, no. 1, 1 July 2004 (2004-07-01), pages 31-41, XP002484358 ISSN: (43) Date of publication of application: 1074-7613 04.01.2012 Bulletin 2012/01 • BHATIA MICKIE: "Hematopoiesis from human embryonic stem cells." ANNALS OF THE NEW (73) Proprietor: Cellular Dynamics International, Inc. YORK ACADEMY OF SCIENCES JUN 2007 LNKD- Madison, WI 53711 (US) PUBMED:17332088, vol. 1106, June 2007 (2007-06), pages 219-222, XP007912752 ISSN: (72) Inventors: 0077-8923 • RAJESH, Deepika • KENNEDY MARION ET AL: "Development of the Madison, WI 53711 (US) hemangioblast defines the onset of • LEWIS, Rachel hematopoiesis in human ES cell differentiation Madison, WI 53711 (US) cultures" BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol.
    [Show full text]
  • An Introduction to Stem Cell Biology
    An Introduction to Stem Cell Biology Michael L. Shelanski, MD,PhD Professor of Pathology and Cell Biology Columbia University Figures adapted from ISSCR. Presentations of Drs. Martin Pera (Monash University), Dr.Susan Kadereit, Children’s Hospital, Boston and Dr. Catherine Verfaillie, University of Minnesota Science 1999, 283: 534-537 PNAS 1999, 96: 14482-14486 Turning Blood into Brain: Cells Bearing Neuronal Antigens Generated in Vitro from Bone Marrow Science 2000, 290:1779-1782 From Marrow to Brain: Expression of Neuronal Phenotypes in Adult Mice Mezey, E., Chandross, K.J., Harta, G., Maki, R.A., McKercher, S.R. Science 2000, 290:1775-1779 Brazelton, T.R., Rossi, F.M., Keshet, G.I., Blau, H.M. Nature 2001, 410:701-705 Nat Med 2000, 11: 1229-1234 Stem Cell FAQs Do you need to get one from an egg? Must you sacrifice an Embryo? What is an ES cell? What about adult stem cells or cord blood stem cells Why can’t this work be done in animals? Are “cures” on the horizon? Will this lead to human cloning – human spare parts factories? Are we going to make a Frankenstein? What is a stem cell? A primitive cell which can either self renew (reproduce itself) or give rise to more specialised cell types The stem cell is the ancestor at the top of the family tree of related cell types. One blood stem cell gives rise to red cells, white cells and platelets Stem Cells Vary in their Developmental capacity A multipotent cell can give rise to several types of mature cell A pluripotent cell can give rise to all types of adult tissue cells plus extraembryonic tissue: cells which support embryonic development A totipotent cell can give rise to a new individual given appropriate maternal support The Fertilized Egg The “Ultimate” Stem Cell – the Newly Fertilized Egg (one Cell) will give rise to all the cells and tissues of the adult animal.
    [Show full text]
  • 10 11 Cyto Slides 81-85
    NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010 Slide 081 Diagnosis: MDS to AML 9 WBC 51.0 x 10 /L 12 Available data: RBC 3.39 x 10 /L 72 year-old female Hemoglobin 9.6 g/dL Hematocrit 29.1 % MCV 86.0 fL Platelet count 16 x 109 /L The significant finding in this case of Acute Myelogenous Leukemia (AML) was the presence of many blast forms. The participant median for blasts, all types was 88. The blast cells in this case (Image 081) are large, irregular in shape and contain large prominent nucleoli. It is difficult to identify a blast cell as a myeloblast without the presence of an Auer rod in the cytoplasm. Auer rods were reported by three participants. Two systems are used to classify AML into subtypes, the French- American-British (FAB) and the World Health Organization (WHO). Most are familiar with the FAB classification. The WHO classification system takes into consideration prognostic factors in classifying AML. These factors include cytogenetic test results, patient’s age, white blood cell count, pre-existing blood disorders and a history of treatment with chemotherapy and/or radiation therapy for a prior cancer. The platelet count in this case was 16,000. Reduced number of platelets was correctly reported by 346 (94%) of participants. Approximately eight percent of participants commented that the red blood cells in this case were difficult to evaluate due to the presence of a bluish hue around the red blood cells. Comments received included, “On slide 081 the morphology was difficult to evaluate since there was a large amount of protein surrounding RBC’s”, “Slide 081 unable to distinguish red cell morphology due to protein” and “Unable to adequately assess morphology on slide 081 due to poor stain”.
    [Show full text]
  • Stem Cell Therapy for Neurodegenerative Diseases
    Review Stem Cell Therapy for Neurodegenerative Diseases Hanyang Med Rev 2015;35:229-235 http://dx.doi.org/10.7599/hmr.2015.35.4.229 1 2,3 2,3 pISSN 1738-429X eISSN 2234-4446 Jong Zin Yee , Ki-Wook Oh , Seung Hyun Kim 1Hanyang University College of Medicine, Seoul, Korea 2Department of Neurology, Hanyang University College of Medicine, Seoul, Korea 3Cell Therapy Center for Neurologic Disorders, Hanyang University Hospital, Seoul, Korea Neurodegenerative diseases are the hereditary and sporadic conditions which are charac- Correspondence to: Seung Hyun Kim Department of Neurology, Hanyang terized by progressive neuronal degeneration. Neurodegenerative diseases are emerging University College of Medicine, as the leading cause of death, disabilities, and a socioeconomic burden due to an increase 222 Wangsimni-ro, Seongdong-gu, in life expectancy. There are many neurodegenerative diseases including Alzheimer’s dis- Seoul 04763, Korea Tel: +82-2-2290-8371 ease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and multiple Fax: +82-2-2296-8370 sclerosis, but we have no effective treatments or cures to halt the progression of any of E-mail: [email protected] these diseases. Stem cell-based therapy has become the alternative option to treat neuro- degenerative diseases. There are several types of stem cells utilized; embryonic stem cells, Received 4 September 2015 Revised 6 October 2015 induced pluripotent stem cells, and adult stem cell (mesenchymal stem cells and neural Accepted 13 October 2015 progenitor cells). In this review, we summarize recent advances in the treatments and the This is an Open Access article distributed under limitations of various stem cell technologies.
    [Show full text]
  • Blood Lab First Week
    Blood Lab First Week This is a self propelled powerpoint study atlas of blood cells encountered in examination of the peripheral blood smear. It is a requirement of this course that you begin review of these slides with the first day of class in order to familiarize yourself with terms used in describing peripheral blood morphology. Laboratory final exam questions are derived directly from these slides. The content of these slides may duplicate slides (1-37) listed on the Hematopathology Website. You must familiarize yourself with both sets of slides in order to have the best learning opportunity. Before Beginning This Slide Review • Please read the Laboratory information PDF under Laboratory Resources file to learn about – Preparation of a blood smear – How to select an area of the blood smear for review of morphology and how to perform a white blood cell differential – Platelet estimation – RBC morphology descriptors • Anisocytosis • Poikilocytosis • Hypochromia • Polychromatophilia Normal blood smear. Red blood cells display normal orange pink cytoplasm with central pallor 1/3-1/2 the diameter of the red cell. There is mild variation in size (anisocytosis) but no real variation in shape (poikilocytosis). To the left is a lymphocyte. To the right is a typical neutrophil with the usual 3 segmentations of the nucleus. Med. Utah pathology Normal blood: thin area Ref 2 Normal peripheral blood smear. This field is good for exam of cell morphology, although there are a few minor areas of overlap of red cells. Note that most cells are well dispersed and the normal red blood cell central pallor is noted throughout the smear.
    [Show full text]
  • ORIGINAL ARTICLE PML–Rara Initiates Leukemia by Conferring Properties of Self-Renewal to Committed Promyelocytic Progenitors
    Leukemia (2009) 23, 1462–1471 & 2009 Macmillan Publishers Limited All rights reserved 0887-6924/09 $32.00 www.nature.com/leu ORIGINAL ARTICLE PML–RARa initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors S Wojiski1,2, FC Guibal3, T Kindler1,2, BH Lee1,2, JL Jesneck4,5, A Fabian1,2, DG Tenen3,6 and DG Gilliland1,2,6 1Division of Hematology, Brigham and Women’s Hospital, Boston, MA, USA; 2Department of Genetics, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA; 3Department of Hematology/Oncology, Harvard Institutes of Medicine, Boston, MA, USA; 4Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA; 5Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA and 6Harvard Stem Cell Institute, Harvard University, Boston, MA, USA Acute promyelocytic leukemia (APL) is characterized by the leukemia stem cells (LSCs) are rare cells contained within hyperproliferation of promyelocytes, progenitors that are the more primitive CD34 þ CD38À population, resembling committed to terminal differentiation into granulocytes, making it an ideal disease in which to study the transforming potential transformed hematopoietic stem cells (HSCs). LSC activity was of less primitive cell types. We utilized a murine model of APL in shown by these investigators in all AML subtypes tested, but which the PML–RARa oncogene is expressed from the were not shown in acute promyelocytic leukemia (APL) endogenous cathepsin G promoter to test the hypothesis that associated with the expression of the PML–RARa fusion as a leukemia stem cell (LSC) activity resides within the differen- consequence of an acquired t(15;17).
    [Show full text]
  • Stem Cell Differentiation Investigation • 1 C L a S S S E S S I O N
    14 Stem Cell Differentiation investigation • 1 c l a s s s e s s i o n Overview BaCKgrOund infOrMatiOn To investigate how embryonic stem cells become specialized Stem cells and precursors cells cells, students draw from a set of colored chips that represent A stem call produces daughter cells that might remain as specific molecular factors that determine the next step of stem cells or begin a pathway of differentiation into one of a specialization. They discuss the paths stem cells take as they variety of specialized cell types. Stem cells are classified into differentiate into specialized cells. three groups, depending on where they are on the pathway toward differentiation. Totipotent stem cells can produce any Key COntent kind of cell in the body, and have an unlimited ability to self- renew. The embryonic cells that form during the first few 1. Stem cells can produce a variety of specialized cells. divisions after an egg is fertilized are totipotent. Pluripotent 2. The process by which stem cells produce specialized stem cells can become almost any type of cell in the body, descendent cells is called differentiation. except the cells of the placenta and certain other uterine tis- sues. Totipotent stem cells become pluripotent after three or Materials and advanCe PreParatiOn four divisions. Multipotent stem cells produce only certain For the teacher types of cells. For example, one line of multipotent stem cells Transparency 14.1, “The Organization of Multicellular gives rise to all the blood cells, including red and white blood Organisms” cells. Adult stem cells are multipotent.
    [Show full text]
  • Difference Between Promyelocyte and Myelocyte Key Difference
    Difference Between Promyelocyte and Myelocyte www.differencebetween.com Key Difference - Promyelocyte vs Myelocyte Granulated blood cells include eosinophils, basophils, and neutrophils which participate in a variety of functions in the body. The precursor stem cells of these cells which arise from the hematopoietic stem cells are of the myeloid lineage. Myeloblasts are the precursor cells of granulated blood cells. Myeloblasts then mature into promyelocytes, myelocytes, metamyelocytes, bands, and segments to finally give rise to granulocytes in the peripheral blood tissue. The development process is known as Granulopoiesis. Promyelocyte is the second stage of Myeloblast development. Myelocyte is the third stage of Myeloblast development. The key difference between the promyelocyte and the myelocyte is the level of differentiation it exhibits. Promyelocytes do not show differentiation while myelocytes show differentiation. What is a Promyelocyte? Promyelocyte is the second stage of the Myeloblast development process. The promyelocyte is larger than the myeloblast. It has a diameter of 12-25µm and is the largest cell type in the myeloid series. It has a prominent nucleus, and the nucleus is placed slightly intended in the cytoplasm. Chromatin and nucleoli are prominent in this. Final structures of chromatin can be identified through microscopic observations. Towards the complete maturation of the promyelocyte, the chromatins appear as well-condensed structures. The condensed chromatin is placed along the nuclear membrane. The cytoplasm of the promyelocyte is granulated, and these granules are termed as the primary azurophilic granules. Since the promyelocyte is not differentiated, it is formed of a basophilic cytoplasm. The cell organelle organization is prominent in the promyelocyte stage of the blood cells.
    [Show full text]
  • Advanced Blood Cell Identification
    ADVANCED BLOOD CELL ID: LEUKOCYTES AND ERYTHROCYTES IN AN ACUTE LEUKEMIA Educational commentary is provided for participants enrolled in program #259- Advanced Blood Cell Identification. This virtual blood cell identification program includes case studies with more difficult challenges. To view the blood cell images in more detail, click on the sample identification numbers underlined in the paragraphs below. This will open a virtual image of the selected cell and the surrounding fields. If the image opens in the same window as the commentary, saving the commentary PDF and opening it outside your browser will allow you to switch between the commentary and the images more easily. Click on this link for the API ImageViewerTM Instructions. Learning Outcomes After completing this exercise, participants should be able to: • Discuss morphologic characteristics of normal peripheral blood leukocytes. • Describe morphologic features of immature granulocytes. • Identify morphologic abnormalities in erythrocyte shape and chromaticity/coloration. Case Study An 18 year old male was seen by his physician for bruising and severe nosebleeds. His CBC results are as follows: WBC=7.5 x 109/L, RBC=2.79 1012/L, Hgb=8.7 g/dL, Hct=24.6%, MCV=88 fL, MCH=31 pg, MCHC=35 g/dL, RDW=18.4%, Platelet=41 x 109/L, MPV=10.4. Educational Commentary The cells selected for identification and discussion in this exercise are from the peripheral blood smear of an 18 year old man diagnosed with acute promyelocytic leukemia (APL). APL is also referred to as acute myeloid leukemia, M3 (AML-M3). As with other acute leukemias, APL has a rapid onset.
    [Show full text]
  • Henry Ford Hospital Clinicopathological Conference: Metamorphosis in Chronic Granulocytic Leukemia in a 60-Year-Old Man
    Henry Ford Hospital Medical Journal Volume 28 Number 1 Article 7 3-1980 Henry Ford Hospital Clinicopathological Conference: Metamorphosis in chronic granulocytic leukemia in a 60-year-old man Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation (1980) "Henry Ford Hospital Clinicopathological Conference: Metamorphosis in chronic granulocytic leukemia in a 60-year-old man," Henry Ford Hospital Medical Journal : Vol. 28 : No. 1 , 37-46. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol28/iss1/7 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. Henry Ford Hosp Med Journal Vol 28, No 1, 1980 Henry Ford Hospital Clinicopathological Conference Metamorphosis in chronic granulocytic leukemia in a 60-year-old man Participants: Protocol: Dr. Ellis J. Van Slyck, Department of Internal Medicine, Division of Hematology Discussant: Dr. Robert K. Nixon, Department of Internal Medicine, Second Medical Division Radiology: Dr. Mark C. Weingarden, Department of Diagnostic Radiology Pathology: Dr. John W. Rebuck, Department of Pathology, Division of Hematology Case Presentation As an outpatient, his myleran dosage was gradually tapered as the This 60-year-old white man came to Henry Ford Hospital in blood counts responded. On February 27, the white count was December 1975, complaining of increased fatigability over the 40,000 and the platelet count 400,000. On May 10, the white preceding year.
    [Show full text]
  • The Possible Role of Mutated Endothelial Cells in Myeloproliferative Neoplasms by Mirko Farina, Domenico Russo, and Ronald Hoffman
    The possible role of mutated endothelial cells in myeloproliferative neoplasms by Mirko Farina, Domenico Russo, and Ronald Hoffman Received: February 17, 2021. Accepted: June 28, 2021. Citation: Mirko Farina, Domenico Russo, and Ronald Hoffman. The possible role of mutated endothelial cells in myeloproliferative neoplasms. Haematologica. 2021 Jul 29. doi: 10.3324/ haematol.2021.278499. [Epub ahead of print] Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process. REVIEW ARTICLE The possible role of mutated endothelial cells in myeloproliferative neoplasms Ferrata Storti Foundation Mirko Farina,1 Domenico Russo1 and Ronald Hoffman2 1Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy and 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA ABSTRACT yeloproliferative neoplasms (MPN) are chronic, clonal hemato- logic malignancies characterized by myeloproliferation and a Mhigh incidence of vascular complications (thrombotic and bleeding).
    [Show full text]